Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
27
LTRN Quote, Financials, Valuation and Earnings
Last price:
$3.88
Seasonality move
:
3.04%
Day range:
$3.62 - $3.90
52-week range:
$2.55 - $6.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.37x
Volume:
70.6K
Avg. volume:
97.3K
1-year change:
7.14%
Market cap:
$41.9M
Revenue:
--
EPS (TTM):
-$1.75
Analysts' Opinion
-
Consensus RatingLantern Pharma, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.00, Lantern Pharma, Inc. has an estimated upside of 486.67% from its current price of $3.75.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 100% downside risk from its current price of $3.75.
Fair Value
-
According to the consensus of 2 analysts, Lantern Pharma, Inc. has 486.67% upside to fair value with a price target of $22.00 per share.
LTRN vs. S&P 500
-
Over the past 5 trading days, Lantern Pharma, Inc. has overperformed the S&P 500 by 3.27% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Lantern Pharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lantern Pharma, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Lantern Pharma, Inc. reported revenues of --.
Earnings Growth
-
Lantern Pharma, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Lantern Pharma, Inc. reported earnings per share of -$0.39.
Enterprise value:
29.7M
EV / Invested capital:
3.07x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.23x
EV / Free cash flow:
-1.76x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$64.4K
Return On Assets:
-87.59%
Net Income Margin (TTM):
--
Return On Equity:
-109.15%
Return On Invested Capital:
-107.94%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$169.4K | -$183.6K | -$64.4K | -$47.9K | -$4.1K | |
| Operating Income | -$16.8M | -$21.2M | -$19.7M | -$5.2M | -$4.3M | |
| EBITDA | -$16.7M | -$21M | -$19.6M | -$5.1M | -$4.3M | |
| Diluted EPS | -$1.40 | -$1.77 | -$1.75 | -$0.42 | -$0.39 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $76.3M | $62M | $47.4M | $29.9M | $13.5M | |
| Total Assets | $77.6M | $62.2M | $47.8M | $30.3M | $13.6M | |
| Current Liabilities | $1.8M | $3.1M | $2.3M | $3.6M | $4M | |
| Total Liabilities | $1.9M | $3.1M | $2.4M | $3.7M | $4M | |
| Total Equity | $75.7M | $59M | $45.4M | $26.6M | $9.6M | |
| Total Debt | $241K | -- | $106.5K | $94K | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$13.6M | -$17.2M | -$16.9M | -$5.6M | -$4.6M | |
| Cash From Investing | -$583.5K | $178.3K | $16.2M | $680.3K | $5.9M | |
| Cash From Financing | -- | -$433.3K | $971.8K | $12K | $971.8K | |
| Free Cash Flow | -$13.7M | -$17.2M | -$16.9M | -$5.6M | -$4.6M | |
LTRN
Sector
Market Cap
$41.9M
$28.5M
Price % of 52-Week High
61.3%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-1.97%
-1.33%
1-Year Price Total Return
7.14%
-20.32%
Beta (5-Year)
1.610
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.66
200-day SMA
Sell
Level
$3.80
Bollinger Bands (100)
Sell
Level
3.62 - 4.54
Chaikin Money Flow
Sell
Level
-403.9K
20-day SMA
Buy
Level
$3.47
Relative Strength Index (RSI14)
Buy
Level
53.97
ADX Line
Buy
Level
16.67
Williams %R
Sell
Level
-16.8224
50-day SMA
Sell
Level
$3.86
MACD (12, 26)
Buy
Level
0.08
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Sell
Level
-807.2K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.3392)
Sell
CA Score
(Annual)
Level (-1.5366)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (8.9142)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Stock Forecast FAQ
In the current month, LTRN has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LTRN average analyst price target in the past 3 months is $22.00.
-
Where Will Lantern Pharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lantern Pharma, Inc. share price will rise to $22.00 per share over the next 12 months.
-
What Do Analysts Say About Lantern Pharma, Inc.?
Analysts are divided on their view about Lantern Pharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lantern Pharma, Inc. is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Lantern Pharma, Inc.'s Price Target?
The price target for Lantern Pharma, Inc. over the next 1-year time period is forecast to be $22.00 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LTRN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lantern Pharma, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LTRN?
You can purchase shares of Lantern Pharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lantern Pharma, Inc. shares.
-
What Is The Lantern Pharma, Inc. Share Price Today?
Lantern Pharma, Inc. was last trading at $3.88 per share. This represents the most recent stock quote for Lantern Pharma, Inc.. Yesterday, Lantern Pharma, Inc. closed at $3.75 per share.
-
How To Buy Lantern Pharma, Inc. Stock Online?
In order to purchase Lantern Pharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LTRN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LTRN
Sector
P/E ratio
--
23.75x
PEG ratio
-0.23x
-0.01x
P/B ratio
4.37x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
LTRN
Sector
Revenue growth
--
4.85%
Earnings growth
7.88%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.47
-$0.20
Profitability
LTRN
Sector
Profitability FY 2024
-$190.5K
$3.6M
Return on invested capital
-107.94%
-30.98%
Return on assets
-87.59%
-27.62%
Return on equity
-109.15%
-36.69%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
12
Balance Sheet
LTRN
Sector
Total cash
$12.4M
$27.2M
Short term investments
$16.5M
$25.7M
Total assets
$25.6M
$79.7M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.18% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
